You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

  • In development
  • Reference number: GID-TA11385
  • Expected publication date:  25 February 2026
  • Project information
  • Project documents

On this page

  1. Draft guidance
  2. Declaration of interests
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6338

Documents

Documents created during the development process.

Draft guidance

  • Draft guidance

  • Committee papers (PDF 6.1 MB)

    Published:
    01 October 2025
  • Equality and health inequalities assessment (downloadable version) (PDF 131 KB)

    Published:
    01 October 2025
  • Public committee slides (PDF 357 KB)

    Published:
    01 October 2025
  • Draft guidance (downloadable version) (PDF 294 KB)

    Published:
    01 October 2025
  • Draft guidance (online commenting)

Declaration of interests

  • Register of interests (PDF 166 KB)

    Published:
    17 October 2025

Invitation to participate

  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 191 KB)

    Published:
    07 February 2025
  • Final stakeholder list (PDF 134 KB)

    Published:
    07 February 2025
  • Equality impact assessment (downloadable version) (PDF 100 KB)

    Published:
    07 February 2025
  • Final scope (PDF 125 KB)

    Published:
    07 February 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6338

  • Draft matrix post referral (PDF 179 KB)

    Published:
    13 November 2024
  • Draft scope post referral (PDF 188 KB)

    Published:
    13 November 2024
Back to top